Research-grade material. A Janoshik report for this compound is available on request. For research use only.
An EPO Analogue Built to Leave the Blood Alone
Erythropoietin does two things in the body, and for most of its research history only one of them mattered to drugmakers. It tells bone marrow to make red blood cells, and separately, it activates a tissue-protective signaling pathway that has nothing to do with blood at all. ARA-290, also known by its developmental name Cibinetide, was engineered specifically to isolate the second effect and leave the first one out. Researchers built it from the helix-B surface domain of EPO, the region responsible for tissue protection, without the domain responsible for red blood cell production.
That design choice is the reason ARA-290 shows up in the research literature at all. A molecule that activates a repair pathway without also touching red blood cell counts is a different research tool than EPO itself, and it is the reason investigators pursued it as a candidate for nerve and tissue repair research rather than as another erythropoiesis agent.
The Innate Repair Receptor
ARA-290 is described in the literature as a selective agonist of the Innate Repair Receptor, a heterodimeric complex formed by the erythropoietin receptor (EPOR) and CD131, also called the beta-common receptor. This receptor pairing is distinct from the classical EPOR homodimer that governs red blood cell production. Investigators have proposed that Innate Repair Receptor activation sits upstream of several tissue-protective processes: anti-inflammatory signaling, resistance to programmed cell death, and repair-oriented cellular activity, as opposed to scarring.
Mechanistic work has traced part of this activity to inhibition of the NF-kB p65 subunit, dependent on CD131 and JAK2 signaling. A 2017 study in a colitis model examined how Cibinetide affects innate immune cell function and reported a dampening effect on the inflammatory activity driving disease course in that model (PubMed 29026145). A separate 2018 study examined Cibinetide in a genetic diabetes model with impaired wound healing, reporting that activation of the EPOR-beta common receptor complex improved wound healing measures in that model (PubMed 29223734).
These are research-model findings. They describe what investigators observed in specific experimental systems, not a property the compound is being marketed to deliver.
The Human Trials: Sarcoidosis-Associated Small Fiber Neuropathy
ARA-290’s most substantial published human data comes from a research program targeting small fiber neuropathy in sarcoidosis, a rare inflammatory disease that can damage the small nerve fibers responsible for pain and temperature sensation.
The pilot trial (2013). A randomized, double-blind, placebo-controlled exploratory study enrolled 22 sarcoidosis study participants with small fiber neuropathy symptoms. Participants received either ARA-290 (2mg, administered intravenously three times weekly for four weeks) or placebo. Researchers measured the Small Fiber Neuropathy Symptom Inventory Questionnaire score and reported a significant improvement in the treatment group compared with placebo (PubMed 23168581).
The phase 2b trial (2017). A larger randomized, placebo-controlled, two-center study examined daily subcutaneous dosing at 1mg, 4mg, or 8mg against placebo over 28 days in 64 study participants with painful sarcoid neuropathy. The trial’s primary endpoint was corneal nerve fiber area, measured by corneal confocal microscopy as a marker of small nerve fiber loss and repair. The study met this endpoint at the 4mg dose, reporting a placebo-corrected increase in corneal nerve fiber area of 697 square micrometers (P=0.012), a treatment effect researchers described as roughly a 23 percent increase from baseline (PubMed 28475703, Invest Ophthalmol Vis Sci 2017;58(6):BIO52-60).
Read plainly: two named trials, in one specific patient population, measuring one specific structural endpoint. Neither trial describes a general nerve-health effect in people without this condition, and neither is a statement about what the compound does for a reader.
What the Research Does Not Establish
Read this part twice. The honest limits matter more than the headlines.
- The company behind these trials, Araim Pharmaceuticals, ceased operations. ARA-290 received orphan drug designation for sarcoidosis-associated small fiber neuropathy, but it was never taken to full FDA approval, and no Phase III replication trial was ever completed. As of this writing, no active clinical trials for ARA-290 or Cibinetide are registered anywhere. This is real, published trial data on a compound whose commercial development has stopped, not an actively advancing drug candidate.
- Both human trials studied a single, rare disease population: sarcoidosis study participants with small fiber neuropathy. Researchers have not established these results in healthy adults or in the general population.
- The trials measured a defined structural marker (corneal nerve fiber area) and a symptom questionnaire score over four weeks. They were not built to show broader nerve-repair or recovery outcomes, and they say nothing about timeframes outside the 28-day and 4-week windows studied.
- The mechanism papers describe research-model findings in colitis and diabetic wound-healing systems in mice, not human outcomes.
- This page is a research summary only. It does not say the compound does anything “for you.”
Where This Material Stands
We have not found another vendor in this category naming this compound’s actual trial history with this level of attribution. ARA-290 is a new addition to Etched’s research catalog. Where an independent laboratory report exists for a compound, the measurements are published on the COA page, including the compounds we hold no report for.
Further Reading
For the at-a-glance summary, see ARA-290 Research.
Buyer-intent tag
Neuropathic research / Tissue-protective signaling
Research Use Only. ARA-290 (Cibinetide) is supplied for research use only and is not for human consumption, diagnosis, treatment, or any clinical or therapeutic application. This material is intended solely for use by qualified researchers in controlled laboratory settings. Nothing in this article describes a property the compound delivers or constitutes a recommendation for use in humans. All clinical-trial endpoints referenced above are attributed to their named studies and study populations and describe only what investigators measured or observed.
Research-grade material. A Janoshik report for this compound is available on request. For research use only.
For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Nothing on this page is medical advice, a health claim, or a recommendation to use.